BNTX
BioNTech SE
BNTX trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over BNTX overall, supported by stronger fundamentals and stronger modeled upside.
BNTX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Strong | |
| Strong |
BNTX's cash flow and balance sheet are currently strong, but its revenue and profitability are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
BNTX PE Valuation
BNTX has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
BNTX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect BNTX's losses to grow, with revenue declining. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
BNTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$7.48 | -$5.88 |
| Q1 2026 | -$5.65 | -$2.03 |
| Q4 2025 | -$5.20 | -$2.05 |
| Q3 2025 | -$2.63 | -$0.32 |
| Q2 2025 | -$1.60 | +$0.84 |
| Q1 2025 | -$3.62 | -854% |
| Q4 2024 | -$3.15 | -175% |
| Q3 2024 | -$2.31 | -119% |
BNTX lost $7.48 per share over the past year, and its loss has widened in each of the last four quarters.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over BNTX on earnings quality, reporting a profit while its opponent remains loss making.
BNTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $117.3M | -60% |
| Q1 2026 | $133.4M | -34% |
| Q4 2025 | $998.6M | -24% |
| Q3 2025 | $1.7B | +22% |
| Q2 2025 | $289.7M | +103% |
| Q1 2025 | $203.1M | -2.6% |
| Q4 2024 | $1.3B | -20% |
| Q3 2024 | $1.4B | +39% |
BNTX's revenue has slid since its 2022 peak: $117M last quarter, down 60% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -898% | -706 points |
| Q1 2026 | -560% | -268 points |
| Q4 2025 | -26% | -38 points |
| Q3 2025 | -3.1% | -3.9 points |
| Q2 2025 | -192% | +559 points |
| Q1 2025 | -292% | -22 points |
| Q4 2024 | 12% | -23 points |
| Q3 2024 | 0.8% | -7.3 points |
BNTX's operating margin was −898% last quarter, down 706 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over BNTX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over BNTX on profitability, with a higher operating margin.
BNTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$49.8M | -106% |
| Q1 2026 | -$539.5M | +$1.1B |
| Q4 2025 | $264M | +$932.4M |
| Q3 2025 | $901.1M | +$1.8B |
| Q2 2025 | $777.7M | -56% |
| Q1 2025 | -$1.6B | -$1.1B |
| Q4 2024 | -$668.4M | -153% |
| Q3 2024 | -$865.1M | -218% |
BNTX's free cash flow has turned positive again: $576M over the past year, against −$2.4B the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over BNTX on cash flow, with more consistent year-over-year improvement.
BNTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +449K shares |
| 1 year | +4.8% | +11.7M shares |
| 3 years | +5.7% | +13.6M shares |
| 5 years | -2.1% | -5.5M shares |
| Available history | +10% | +23.9M shares |
BNTX has 253M diluted shares, up 4.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $146.7M |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
BNTX spent $147M buying back its own shares over the past year, after none the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over BNTX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
BNTX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2024 | -149.4x | Net Cash |
| Q4 2023 | -10.3x | Net Cash |
| Q3 2023 | -3.4x | Net Cash |
| Q2 2023 | -2.3x | Net Cash |
| Q1 2023 | -1.5x | Net Cash |
| Q4 2022 | -1.0x | Net Cash |
| Q3 2022 | -0.9x | Net Cash |
| Q2 2022 | -0.5x | Net Cash |
BNTX has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
BNTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.6 | Neutral |
| Stochastic | 5.7 | Oversold |
BNTX's weekly RSI is 41 (neutral) and its Stochastic is 6 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
BNTX PE vs Healthcare Sector
| Metric | BNTX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
BNTX has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
BNTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $91.1 | 6.7% below |
| 20 week MA | $94.6 | 10% below |
| 50 week MA | $96.6 | 12% below |
| 100 week MA | $101.4 | 16% below |
| 200 week MA | $103.6 | 18% below |
BNTX is in a downtrend: it's below all five of its weekly moving averages, and 18% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over BNTX on trend strength, trading above more of its moving averages.
BNTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $32.6 | $97.0 | +198% |
| 2021 | $97.0 | $255.3 | +163% |
| 2022 | $255.3 | $176.0 | -31% |
| 2023 | $176.0 | $105.5 | -40% |
| 2024 | $105.5 | $114.0 | +8% |
| 2025 | $114.0 | $94.5 | -17% |
| 2026 YTD | $94.5 | $85.0 | -10% |
BNTX's yearly returns have swung widely, from +198% in 2020 to −40% in 2023. It's down 10% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over BNTX on returns for 2026, with the stronger performance.